Abstract Ferumoxytol, an iron nanoparticle used as an intravascular contrast agent for perfusion magnetic resonance imaging (MRI), has never been explored in the pediatric population. The purpose of this prospective study is to characterize the vascular and permeability properties of pediatric brain tumors using two contrast agents during a single imaging session: ferumoxytol for dynamic susceptibility weighted contrast (DSC) MRI and gadoteridol for dynamic contrast-enhanced (DCE) MRI. In a single imaging session, patients received intravenous ferumoxytol for DSC MRI followed by gadoteridol for DCE MRI. Relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF), transfer coefficient (K trans ), and extravascular extracellular space volume fraction (v e ) of the brain lesions were calculated. Patients underwent serial imaging sessions over the course of 2 years. Of the 7 patients enrolled thus far, none has experienced an adverse event. Two patients with medulloblastoma were enrolled preoperatively. In the first, rCBV max , rCBF, K trans max, and v e max values were 3.74, 3.12, 0.47 min -1 , and 0.08, respectively, while in the second patient, rCBV max , rCBF, K trans max, and v e max values were 4.72, 3.47, 0.60 min -1 , and 0.05, respectively. Four patients were enrolled after new gadolinium enhancement was noted in the tumor resection cavity. In 80 % of these lesions, rCBV was \1 suggestive of pseudoprogression secondary to radiochemotherapy. These preliminary results demonstrate that use of ferumoxytol and gadoteridol contrast agents during a single imaging session is feasible, safe, and appears useful for assessing tumor perfusion and permeability characteristics in children.
Introduction
Current magnetic resonance imaging (MRI) that relies upon gadolinium based contrast agents (GBCA) to evaluate brain tumors in children is frequently confounded by false positive results from post-surgical changes and pseudoprogression [1, 2] following radiochemotherapy. Imaging that more accurately predicts the true extent and viability of pediatric brain tumors is of paramount importance, particularly when the imaging can be completed in one session thereby alleviating the need for repeated sedation.
Ferumoxytol (AMAG) is an ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle, with an FDA orphan designation for use as an MRI contrast agent in brain tumor imaging [3] . This agent has demonstrated excellent perfusion brain tumor imaging in adults [4, 5] . The use of ferumoxytol in a pediatric population has never been reported.
Dynamic susceptibility contrast (DSC) MRI allows for the determination of relative cerebral blood flow (rCBF) and relative cerebral blood volume (rCBV) in brain tumors. Because it remains intravascular at early time points [6] , ferumoxytol is likely a more accurate marker than GBCA for determining active tumor [7, 8] . Dynamic contrastenhanced (DCE) MRI allows for the determination of the permeability, or ''leakiness,'' of tumor vasculature such as transfer coefficient (K trans ) and extravascular extracellular space volume fraction (v e ). In normal brain with an intact blood brain barrier (BBB), K trans & 0 min -1 [9, 10] and v e is unmeasurable [11] . Obtaining DSC and DCE MRI in a single imaging session has not been previously reported using both ferumoxytol and GBCA.
An increasingly important problem in pediatric brain tumor imaging is pseudoprogression, an inflammatory brain reaction caused by radiochemotherapy. Our group's findings suggest that pseudoprogression in adults can be differentiated from true tumor progression more accurately using ferumoxytolbased rather than GBCA-based rCBV measurements with a cut-off ratio of 1.75 [7, 8] . Since patients with pseudoprogression usually recover or stabilize spontaneously without treatment [12] , an accurate non-invasive diagnostic method is desirable to avoid unnecessary surgical intervention. The purpose of this prospective study is to more accurately characterize tumor vascular and permeability properties and distinguish true tumor progression from pseudoprogression in pediatric brain tumors using ferumoxytol-based DSC MRI combined with GBCA-based DCE MRI in a single session.
Materials and methods
This prospective study was approved by the Oregon Health & Science University (OHSU) Institutional Review Board. Consent to be enrolled in this study was obtained from the patient (if applicable) and two parents or legal guardians. Patients included in the study were age 18 years or younger and had an established histologic diagnosis of a brain tumor.
Study design
Based on prior studies [5, 7] , the starting dose in this study was B2 mg Fe/kg to acquire the best imaging results at the applied magnetic field strength. The protocol required removal from the study if subjects developed any grade C3 toxicities from ferumoxytol as defined by the Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [13] . As necessary, monitored anesthesia care and sedation were provided by the OHSU Department of Pediatric Anesthesia. Each patient had a baseline MRI study with any GBCA within 6 weeks prior to enrollment. Laboratory testing included creatinine, calculated GFR, and b-HCG (in females of child bearing potential) within 3 weeks prior to each MRI session. Neurological examinations were performed and vital signs were monitored before and after each MRI session.
MRI acquisition parameters
All MRI scans were performed on 3T whole-body MRI systems (either TIM Trio, Siemens Medical Solutions, Erlangen, Germany or Achieva, Philips Healthcare, Best, The Netherlands) with a body radio frequency (RF) coil for transmitting and a 12-channel head matrix (Siemens) or an 8-channel sensitivity-encoding head (Philips) coil for signal receiving.
For T 1 -weighted spin echo (SE) images, a repetition time (TR)/echo time (TE) of 900/10 was used, and up to 44 slices with a 2-mm thickness without gap were obtained. A field of view (FOV) of 240 9 240 mm and an acquisition matrix of 256 9 256 were chosen. For T 2 -weighted turbo spin echo (TSE) images, a TR/TE of 9,000/93 was used at a slice thickness of 2 mm without gap. The TSE factor was 9, while the FOV was 240 9 240 mm with an acquisition matrix of 256 9 256. For DSC MRI, dynamic T 2 *-weighted images were acquired using a gradient-echo echo-planar imaging pulse sequence (TR, 1,500 ms; TE, 20 ms; flip angle (FA), 45°; FOV, 192 9 192 mm; matrix, 64 9 64; and 27 interleaved slices with 3-mm thickness and 0.9-mm gap). After an initial baseline period of 7 series of 27 image slices (11 s), a rapid bolus of ferumoxytol was administered intravenously at a rate of 3 mL/ s; followed immediately by 20 mL of saline flush at the same rate. DSC data collection continued for an additional 90 series. DCE MRI employs a 3D fast gradient recalled echo sequence (TR, 5.4-5.8 ms; FA, 15°; FOV, 240 9 180 mm 2 ; matrix, 256 9 192; 16 or 32 slices; and 96 to 108 DCE time points). 0.1 mmol/kg gadoteridol was administered approximately 1 min after commencement of DCE MRI. Multiple FA data for pre-gadoteridol T 1 estimation was not collected in order to minimize time of pediatric sedation.
Image analysis
All first-pass DSC MRI data were processed using Lupe (Lund, Sweden) perfusion software. The arterial input function (AIF) was determined from the middle cerebral artery contralateral to the enhancing lesion. Relative CBV measurements were calculated from regions of interest (ROI) that were placed in regions of highest perfusion seen on the rCBV color overlay maps. Four separate ROI measurements were made, and the maximum value (rCBV max ) was recorded to provide the highest intra-and interobserver reproducibility [14] . The rCBF measurements were taken from areas identical to the region of the rCBV max . The mean of 3 regions of contralateral white matter was used as the internal reference standard. The size of the ROIs was kept constant (radius 1.5 mm). Parametric maps were analyzed using ImageJ software (NIH, Bethesda, MD, USA).
All DCE MRI data fitting was performed using nonlinear least squares method with an in-house software package written in MATLAB (MathWorks, Natick, MA, USA). A generic AIF derived from previous DCE MRI studies was used for all pharmacokinetic modeling. Standard Toft's model [15] was used for all cases to fit K trans and v e . Blood volume data was extracted from the DSC MRI using intravascular ferumoxytol. Therefore, blood volume fraction was not modeled in this DCE data because the primary goal of obtaining DCE MRI was to estimate permeability. From pixel by pixel fitting of the entire lesion, heterogenous K trans and v e values were commonly observed in individual lesions. To standardize lesion characterization, maximum pixel value for each individual lesion was reported for these patients. Dynamic contrast enhancement pharmacokinetic modeling was only applied to areas that contained visible enhancement from post GBCA T 1 -weighted images.
Results
From September 2009 to July 2010, 7 patients were enrolled (Table 1) . No patient experienced an adverse event secondary to ferumoxytol administration.
Patient 1
Patient 1, a 5 year old male, presented with nausea, vomiting, and ataxia. Conventional MRI showed a midline posterior fossa mass that enhanced homogeneously on post GBCA T 1 -weighted MRI. Dynamic MRI showed increased rCBV max , rCBF, K trans max, and v e max ( Fig. 1 ; Table 2 ). The patient underwent gross total resection of the lesion. Intraoperatively, the most vascular areas were encountered in the right posterior aspect of the tumor, consistent with the DSC parametric maps. Additionally, intraoperative ultrasound revealed extraordinarily hyperechoic tumor (images unavailable). Pathology demonstrated medulloblastoma. Routine follow up dynamic MRI 4.5 months post operatively showed substantially decreased rCBV max , rCBF, K trans max, and v e max ( Fig. 1 , Table 2 ).
Patient 2
Patient 2, a 9 year old female, was enrolled 1 week following subtotal resection of a medulloblastoma. Postoperative conventional MRI was confounded by artifact from vascular clips and surgical and blood products from the initial resection. Dynamic MRI showed elevated rCBV max , rCBF, K trans max, and v e max ( Fig. 1 ; Table 2 ) in the right posterior aspect of the initial resection cavity in the same area as trace GBCA enhancement on T 1 -weighted MRI. The information from the dynamic MRI was used in preoperative planning for a second surgery and in intraoperative localization of the vascular residual tumor thereby facilitating a gross total resection. As in patient 1, intraoperative ultrasound was used to localize the extraordinarily hyperechoic tumor. Intraoperatively, the anterior portion of the previous resection cavity was found to consist primarily of hemostatic agents with minimal residual tumor. These findings were consistent with low vascularity and permeability in this area as demonstrated by dynamic MRI. Gross total resection of the tumor was achieved and conventional MRI 1 year post operatively demonstrated no recurrence.
Patient 3
Patient 3, a 9-year old male, underwent gross total resection of a medulloblastoma 1 year prior to enrollment. He received adjuvant radiochemotherapy consisting of craniospinal radiation with 54 Gy boost to the posterior fossa in addition to cisplatin, vincristine, and cyclophosphamide. Nine months following the completion of radiation and 7 months following completion of chemotherapy, a new small linear area of enhancement at the tumor resection cavity was noted on post GBCA T 1 -weighted MRI (Fig. 1 ).
Despite increased enhancement on post GBCA T 1 -weighted MRI, DSC MRI values were \1.75 (Table 2) . This same enhancement and perfusion pattern was reconfirmed 15 weeks later ( Fig. 1 ; Table 2 ). No interventions have been pursued, and the patient remains clinically stable more than a year later. (Fig. 2) . Dynamic susceptibility weighted contrast MRI values were \1.75 (Table 2) despite increased post GBCA T 1 -weighted MRI suggestive of pseudoprogression. This same pattern in GBCA enhancement and DSC MRI was reconfirmed 3 months later ( Fig. 2 ; Table 2 ). Dynamic contrast enhancement MRI values were relatively high at both time points likely secondary to differences in the selection of pixels for rCBV max and K trans max. No intervention was pursued and the patient remains clinically stable more than a year later.
Patient 5
Patient 5, a 7-year old male, previously underwent gross total resection of a WHO Grade III anaplastic astrocytoma. Post-operative MRI showed no residual enhancement on post GBCA T 1 -weighted MRI. Adjuvant radiochemotherapy consisted of 60 Gy conformal radiation and temozolomide. Nine months following the completion of radiation, post GBCA T 1 -weighted MRI demonstrated a new small enhancing nodule in the previous resection cavity (Fig. 2) . The patient underwent dynamic MRI but these maps could not be interpreted due to the lesion's ROI incorporating the high-flow branches of the anterior cerebral artery.
Patient 6
Patient 6, a 12 year old male, previously underwent near total resection of a right occipital WHO Grade IV glioblastoma multiforme (GBM). He subsequently received 59 Gy conformal radiation and temozolomide followed by concomitant temozolomide and lomustine. Due to vision deterioration, he underwent repeat resection of this lesion with subsequent maintenance temozolomide. Twenty-one months after completing adjuvant radiotherapy and 6 months after stopping temozolomide, an MRI revealed a new focus of enhancement in the medial aspect of the resection cavity and abnormal T 2 -weighted signal change in the right cerebellar hemisphere (Fig. 3) . DSC MRI values of the occipital and cerebellar lesions were \1.75 ( Table 2 ). The patient died 10 weeks after study enrollment secondary to disease progression of the right cerebellar lesion (Fig. 3) . The occipital lesion remained stable. A follow-up dynamic MRI session was not obtained secondary to the patient's rapid clinical decline and the family elected not to proceed with an autopsy.
Patient 7
Patient 7, a 7-year-old female, underwent biopsy of a right frontotemporal WHO Grade I juvenile pilocytic astrocytoma (JPA) more than 5 years prior to enrollment. She had been treated with adjuvant carboplatin, vincristine and actinomycin in addition to 3 subsequent tumor debulking surgeries. Dynamic susceptibility contrast MRI values of this avidly enhancing region were \1.75 ( Fig. 3 ; Table 2 ), consistent with the historical histological diagnosis of a low-grade glial tumor. Notably, DCE values were relatively high ( Table 2) .
Discussion

Advanced imaging applications
In pediatric medulloblastoma, residual tumor C1.5 cm 2 places the patients in a ''high-risk'' category [16] that is associated with worse prognosis [17] . In case 2, the DSC MRI maps demonstrated the true location of residual tumor better than conventional MRI (Fig. 1 ) thereby facilitating a gross total resection. In case 1, post operative dynamic MRI was used to confirm the resection of all tumor areas of high vascularity and permeability. The use of DSC MRI with ferumoxytol also has important applicability in the evaluation of adjuvant therapy. Differentiating tumor progression from pseudoprogression is critical, as patients often undergo biopsy to help differentiate pseudoprogression from true tumor progression and the presence of pseudoprogression is associated with a more favorable overall survival [18] . The need for advanced imaging assessing perfusion by DSC and permeability by DCE is particularly relevant as these antiangiogenic agents that confound the assessment of tumor progression versus pseudoprogression [19] are being explored in pediatric patients with brain tumors [20, 21] .
In our study, patients 3, 4, 5, and 6 were enrolled to evaluate for pseudoprogression. In cases 3, 4, and 6 the lesions in the resection cavity that displayed high degrees of enhancement on post GBCA T 1 -weighted MRI exhibited rCBV max suggestive of pseudoprogression. In addition, patients 3 and 4 had stable repeat DSC MRI maps.
The limitation in the determination of pseudoprogression using these methods was seen in Patient 6. Although both DSC and DCE maps did not suggest a highly vascular or permeable lesion in the cerebellum (Table 2) , anatomic MRI 6 weeks following the initial dynamic MRI revealed that the lesion had increased in size considerably as seen in both T 2 -weighted and post GBCA T 1 -weighted MRI (Fig. 3) . The patient died approximately 4 weeks later. This inaccuracy of these vascular maps was likely due to the incompatibility of the ROI in this study and the size of the enhancing cerebellar lesion. Each ROI in this study had a radius of 1.5 mm while the size of this particular enhancing lesion was less than 1 mm in diameter. Thus, at JPA juvenile pilocytic astrocytoma least half of the ROI included non-enhancing brain tissue. Based on the results, it is clear that lesions must not only enhance on post GBCA T 1 -weighed MRI, but must be greater than the dynamic imaging pixel resolution to minimize partial volume effect in future studies.
Notably, patients' 3, 4, and 6 DCE maps demonstrated relatively high v e values in the enhancing lesions. The significance of low vascularity and high extravascular extracellular space volume fraction is unknown in this group of patients and warrants further investigation. In patient 7, there was a marked dichotomy in low DSC values and high DCE values. Notably, this was the only patient with a low-grade glioma in this study. This suggests that BBB compromise resulting in increased permeability occurs earlier than increased vascularity in lowgrade tumors but not in high-grade tumors.
The results of the DCE MRI values in this study were variable. Variability of permeability within a tumor and between tumors within an individual has been well-documented in both humans [22, 23] and in animal models [24] . The wider K trans and v e parameter range from DCE MRI may be an indicator of the heterogeneity of tumor growth. Single-pixel hot spots (median K trans & 0.16 min -1 , median v e & 0.17) reported for the group is within the range seen in the literature [11, 25, 26] . Still, DSC MRI using ferumoxytol appears to be more clinically relevant as rCBV has been shown to be the best predictor of tumor grade followed by CBF, and K trans [27] . Future studies will focus on different methods of DCE MRI acquisition and data processing to elucidate how BBB and blood tumor barrier permeability are affected by radiation, chemotherapy, and anti-edema agents such as dexamethasone.
Toxicities
In this study, ferumoxytol doses of 0.7-3 mg/kg Fe were administered to patients without adverse events. In our experience in adults, ferumoxytol doses of 1-2 mg/kg Fe provide optimal dynamic imaging quality [5, 7] and are substantially smaller than the dose of 510 mg Fe administered to adults with end-stage renal disease to treat anemia [28] .
Limitations
The key limitations of this pilot study are the relatively small number of patients, short follow up, and heterogeneous tumor type. Additionally, in order to meet inclusion criteria, the pre-enrollment brain lesion must have enhanced on post GBCA T 1 -weighted MRI to allow for the calculation of K trans . Importantly, we also discovered GBCA enhancing lesions must have a radius greater than 1.5 mm and small lesions near large vessels cannot be evaluated using the aforementioned dynamic MRI techniques. This issue may be due to our DSC MRI FOV of 192 9 192 mm which was selected because it had been used by our group in several prior adult dynamic MRI studies [4, 7, 29] . In future DSC and DCE MRI studies in children, we plan on utilizing smaller FOVs.
Although low rCBV in the face of increased post GBCA T 1 -weighted MRI is suggestive of pseudoprogression [7] , we did not have the opportunity to confirm this by histology in patients 3, 4, and 6. In the case of Patient 2, the effect of artifact from surgical hemostatic agents and metallic vessel clips is unknown in dynamic MRI but certainly has the potential to confound DSC and DCE data. All living patients will continue to be followed with serial dynamic MRI to evaluate change in size or character of their enhancing lesions.
Conclusion
This is the first reported use of ferumoxytol in pediatric patients with brain tumors and the first reported successful dual-contrast single imaging session utilizing ferumoxytolbased DSC and GBCA-based DCE MRI. All patients tolerated ferumoxytol without adverse events in doses of up to 3 mg/kg Fe. We found ferumoxytol-based DSC MRI to be a useful tool preoperatively in devising a tumor resection plan, intraoperatively in localizing the tumor and the most vascular regions of the tumor using ultrasound, and postoperatively in the evaluation of true tumor progression versus pseudoprogression. Dynamic contrast enhanced MRI modeled with the Tofts model was of limited clinical use in our relatively small study group likely secondary to the permeability heterogeneity of each lesion. Based on the pilot data from this study, future studies will be designed using ferumoxytol DSC MRI to focus on the evaluation of pseudoprogression.
